CUE Cue Biopharma Inc

Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually from February 13-14, 2024.

During the presentation, Cue Biopharma’s chief executive officer, Dan Passeri, will provide a corporate update highlighting the latest developments from its lead clinical programs, CUE-101 and CUE-102, its lead preclinical autoimmune program partnered with Ono Pharmaceutical, as well as market opportunities, competitive positioning and key forecasted value-driving 2024 milestones.



Presentation Details

Oppenheimer 34th Annual Healthcare Life Sciences Conference

Date and Time: Tuesday, February 13, 9:20 a.m. EST

Webcast Link:

Presenter: Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma

A live and archived webcast of the presentation will be available on the Events page in the Investors and Media section of the Company’s website at . The webcast will be archived for 30 days.

About Cue Biopharma

Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.

Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information please visit  and follow us on  and .

Investor Contact

Marie Campinell 

Senior Director, Corporate Communications

Cue Biopharma, Inc.

Media Contact

Jonathan Pappas

LifeSci Communications



EN
06/02/2024

Underlying

CUECue Biopharma Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cue Biopharma Inc

 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Announces Pricing of $10 Million Public Offering

Cue Biopharma Announces Pricing of $10 Million Public Offering BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease, today announced the pricing of an underwritten public offering of 35,714,286 shares of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying common stock warrants to purchase an aggregate of 17,857,143 sha...

December 19, 2025 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Announces Proposed Public Offering

Cue Biopharma Announces Proposed Public Offering BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. In addition, Cue Biopharma intends to grant the underwriters an op...

December 18, 2025 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent ...

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights Announced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Company is entitled to receive upfront payments totaling $15M Announced strategic transition in leadership to further enable next stage of growth with disruptive autoimmune therapeutic candidates, most notably CUE-401, the Company’s lead autoimmune asset BOSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing...

November 12, 2025 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Deve...

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors Exclusive collaboration and license agreement focuses on advancing novel T cell therapy “Seed-and-Boost” approach exploiting the mechanism of the CUE-100 series of Immuno-STATs®Novel therapeutic approach is designed to enable in vivo expansion and activation of infused T cell receptor engineered T cells (TCR-Ts) to provide durability, tolerability and enhanced clinical benefit while reducing manufacturing complexityCompelling data generated in preclinical models of m...

November 6, 2025 1 EN
 PRESS RELEASE
Free
CUE Cue Biopharma I...

Cue Biopharma Announces Strategic Transition in Leadership to Further ...

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth with Disruptive Autoimmune Therapeutic Candidates Usman Azam, M.D., is appointed President and Chief Executive Officer of Cue Biopharma, effective September 29, 2025Daniel Passeri, Chief Executive Officer of Cue Biopharma, transitions to Strategic Advisor to provide ongoing support to the Company Cue Biopharma prioritizes autoimmune disease for next stage of growth with focus on advancing first-in-class tolerogenic biologic CUE-401 into the clinic BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- -...

September 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch